Aerie Pharmaceuticals Inc (NASDAQ:AERI) Sellers Increased Their Shorts By 14.66% As Of Apr 17, 2018

April 17, 2018 - By Mary Markley

During Q4 2017 the big money sentiment decreased to 1.2. That’s change of 0.53, from 2017Q3’s 1.73. 23 investors sold all, 48 reduced holdings as Aerie Pharmaceuticals, Inc. ratio dropped. 64 rose holdings while 21 funds acquired holdings. Funds hold 34.86 million shares thus 1.29% more from 2017Q3’s 34.42 million shares.
Kazazian Asset Mgmt Lc holds 0.76% or 12,466 shs in its capital. Jpmorgan Chase & Company accumulated 0% or 19,570 shs. Northern Corp has 426,200 shs. Sei Investments Company invested in 0% or 4,140 shs. Baker Bros Advsrs L P owns 299,356 shs for 0.16% of their capital. Iguana Ltd Limited Liability Company accumulated 85,000 shs. 179,503 are owned by Credit Suisse Ag. Manchester Capital Mgmt Ltd holds 0% or 150 shs in its capital. Eam Invsts holds 52,603 shs or 0.41% of its capital. Vanguard Group Inc has invested 0.01% of its capital in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). Royal Retail Bank Of Canada invested in 0% or 30,364 shs. Intl Gp accumulated 22,322 shs. Moreover, Principal Fincl Gp Inc has 0% invested in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). 77,072 are owned by Essex Invest Ltd Llc. The Nebraska-based Ameritas Investment Prtn has invested 0.01% in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI).

Change of 14.66% for Aerie Pharmaceuticals Inc (NASDAQ:AERI)’s shorted shares was registered. FINRA issued shorted shares of AERI’s total 5.19 million shares. That’s 14.66% up from 4.53M shares. With Average volume 377,200, AERI’s former position will take 14 days to restore. Float short on Aerie Pharmaceuticals Inc is 19.37%.

On during the last trading session the stock increased $0.05 or 0.09%, reaching $53.15.Currently Aerie Pharmaceuticals, Inc. is uptrending after 16.25% change in last April 17, 2017. AERI has 9,111 shares volume. AERI outperformed the S&P500 by 4.70%.

Aerie Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases.The company has $2.10 billion market cap. The Company’s lead product candidate includes Rhopressa, a once-daily eye drop for the reduction of intraocular pressure in patients with glaucoma or ocular hypertension.Currently it has negative earnings. The firm is also developing Roclatan, a once-daily eye drop to reduce IOP that is in Phase III registration trials to treat patients with open-angle glaucoma and ocular hypertension.

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Ratings Coverage

Total analysts of 8 have positions in Aerie Pharmaceuticals (NASDAQ:AERI) as follows: 8 rated it a “Buy”, 0 with “Sell” and 0 with “Hold”. The positive are 100%. The firm has $100.0 highest while $69.0 is the lowest [Target]. The average target $84.38 is 58.76% above the last ($53.15) price. Since October 24, 2017 according to StockzIntelligence Inc Aerie Pharmaceuticals has 11 analyst reports. On Wednesday, January 24 the firm earned “Buy” rating by Canaccord Genuity. On Friday, February 16 the rating was reinitiated by H.C. Wainwright with “Buy”. On Tuesday, January 2 the rating was maintained by Stifel Nicolaus with “Buy”. On Monday, December 18 the stock of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) earned “Buy” rating by Cantor Fitzgerald. On Wednesday, February 28 Cantor Fitzgerald maintained the shares of AERI in report with “Buy” rating. On Thursday, March 29 the firm has “Buy” rating by Mizuho given. The stock rating was maintained by Cowen & Co with “Buy” on Thursday, November 9. On Thursday, March 1 the company was maintained by H.C. Wainwright. On Thursday, November 16 the firm has “Buy” rating by Cantor Fitzgerald given.

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: